MannKind Corp. (MNKD)

[TREND1]

*****For Investors: Rx count is VERY IMPORTANT
WHY ?
Because they will result in $25 million bonuses from SNY
which will help with the short term re financing
that will be required in AUG 2015
............................................................
*** key point in article
3 Questions to Ask Before You Buy a Biotech Stock
120 mil cash vs 203 mil short term debt

The situation is a bit different at MannKind.

MannKind is the maker of the promising inhaled insulin drug Afrezza that won FDA approval last year. Thanks to a licensing deal it cut with Sanofi last summer, MannKind's financial situation is improving; however, a quick look at its balance sheet still raises some red flags.

Specifically, MannKind has $120.8 million in cash, but after adjusting back out the accounting impact of collaboration revenue from Sanofi, it also has $203 million in short-term debt. As a result, MannKind's current ratio is just 0.50, and that could suggest this company may have some financial challenges down the road if Afrezza sales are slow to materialize.


AUG 2015 WILL BE INTERESTING...
QUESTION...Is MNKD price adjusting to this fact ?